Michael Burgess: “While the motion to recommit may be well intentioned, it has a practical effect of killing this bill because the Senate…”

“While the motion to recommit may be well intentioned, it has a practical effect of killing this bill because the Senate has rejected House attempts to refine the Senate bill that was passed by unanimous consent last August. So if you want to provide that right to try for patients, this is the vehicle. Now, interestingly enough, the Food and Drug Administration Administrator, this morning, Dr. Gottlieb, put out a statement. He said that he is: ``. . . ready to implement it in a way that achieves Congress' intent to promote access and protect patients; and build on FDA's longstanding commitment to these important goals.'' Mr. Speaker, I urge people to vote against the motion to recommit and vote for the underlying bill. Let's give patients that expanded access, and I yield back the balance of my time. The SPEAKER pro tempore. Without objection, the previous question is ordered on the motion to recommit. There was no objection. The SPEAKER pro tempore. The question is on the motion to recommit. The question was taken; and the Speaker pro tempore announced that the noes appeared to have it.”